Surmount Formulations Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 17-11-2024
- Paid Up Capital ₹ 1.00 M
as on 17-11-2024
- Company Age 4 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.00 Cr
as on 17-11-2024
- Revenue -87.85%
(FY 2023)
- Profit -53.90%
(FY 2023)
- Ebitda -5691.94%
(FY 2023)
- Net Worth 15.58%
(FY 2023)
- Total Assets -6.73%
(FY 2023)
About Surmount Formulations
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹5.00 Cr.
Dhirendra Mehta and Kavit Mehta serve as directors at the Company.
- CIN/LLPIN
U24304GJ2020PTC116901
- Company No.
116901
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Sep 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Surmount Formulations?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dhirendra Mehta  | Director | 29-Sep-2020 | Current |
| Kavit Mehta | Director | 29-Sep-2020 | Current |
Financial Performance of Surmount Formulations.
Surmount Formulations Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 87.85% decrease. The company also saw a substantial fall in profitability, with a 53.9% decrease in profit. The company's net worth Soared by an impressive increase of 15.58%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Surmount Formulations?
Unlock access to Surmount Formulations's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Surmount Laboratories Private LimitedActive 28 years 9 monthsDhirendra Mehta and Kavit Mehta are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 25 Mar 2021 | ₹5.00 Cr | Open |
How Many Employees Work at Surmount Formulations?
Surmount Formulations has a workforce of 0 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Surmount Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Surmount Formulations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
